BACKGROUND: Serum neurofilament light chain (sNfL) levels represent a promising marker of neuroaxonal injury. They are elevated in several neurological conditions, but their importance in cerebrovascular diseases remains unclear. In a proof of concept study, we compared sNfL levels with clinical characteristics and outcome in patients with cervical artery dissection (CeAD). METHODS: A total of 49 non-traumatic CeAD patients were included. sNfL levels were measured by high-sensitivity electrochemiluminescence immunoassay. Levels were compared with regard to (i) type of presenting symptoms (local symptoms only (n = 8), transient ischemic attack (TIA; n = 10) or ischemic stroke (n = 31)), (ii) stroke severity quantified by National Institute of Health Stroke Scale (NIHSS), (iii) time interval between onset of symptoms and blood sampling and (iv) 3-month outcome as measured by the modified Rankin Scale score. Analyses were performed using univariate and multivariate linear and ordinal regression models. RESULTS: CeAD patients presenting with stroke had significantly higher sNfL levels (median 108.9 pg/ml, interquartile range (37.8-427.7)) than patients with TIA (16.4 pg/ml (8.7-36.3), p = 0.002) or local symptoms (23.4 pg/ml (17.8-30.8), p = 0.0007). Among stroke patients, sNfL levels were positively associated with both NIHSS (p = 0.0002) and time between stroke onset and serum sampling (p = 1.9 × 10-6). Higher sNfL levels were associated with unfavorable outcome at 3 months (OR 4.67, 95% CI 1.69-12.95, p = 0.003). However, this association lost significance after adjustment for NIHSS. The highest sNfL level was observed in a TIA patient who had ischemic stroke 1 day after serum sampling for sNfL measurement. CONCLUSION: sNfL levels were increased in CeAD patients presenting with stroke, correlated with clinical severity and were influenced by the time point of blood sampling. The prognostic meaning of sNfL in CeAD deserves further testing.
BACKGROUND: Serum neurofilament light chain (sNfL) levels represent a promising marker of neuroaxonal injury. They are elevated in several neurological conditions, but their importance in cerebrovascular diseases remains unclear. In a proof of concept study, we compared sNfL levels with clinical characteristics and outcome in patients with cervical artery dissection (CeAD). METHODS: A total of 49 non-traumatic CeADpatients were included. sNfL levels were measured by high-sensitivity electrochemiluminescence immunoassay. Levels were compared with regard to (i) type of presenting symptoms (local symptoms only (n = 8), transient ischemic attack (TIA; n = 10) or ischemic stroke (n = 31)), (ii) stroke severity quantified by National Institute of Health Stroke Scale (NIHSS), (iii) time interval between onset of symptoms and blood sampling and (iv) 3-month outcome as measured by the modified Rankin Scale score. Analyses were performed using univariate and multivariate linear and ordinal regression models. RESULTS: CeAD patients presenting with stroke had significantly higher sNfL levels (median 108.9 pg/ml, interquartile range (37.8-427.7)) than patients with TIA (16.4 pg/ml (8.7-36.3), p = 0.002) or local symptoms (23.4 pg/ml (17.8-30.8), p = 0.0007). Among strokepatients, sNfL levels were positively associated with both NIHSS (p = 0.0002) and time between stroke onset and serum sampling (p = 1.9 × 10-6). Higher sNfL levels were associated with unfavorable outcome at 3 months (OR 4.67, 95% CI 1.69-12.95, p = 0.003). However, this association lost significance after adjustment for NIHSS. The highest sNfL level was observed in a TIApatient who had ischemic stroke 1 day after serum sampling for sNfL measurement. CONCLUSION:sNfL levels were increased in CeAD patients presenting with stroke, correlated with clinical severity and were influenced by the time point of blood sampling. The prognostic meaning of sNfL in CeAD deserves further testing.
Authors: John G Hanly; Alexandra Legge; Lyna Kamintsky; Alon Friedman; Javeria A Hashmi; Steven D Beyea; John Fisk; Antonina Omisade; Cynthia Calkin; Tim Bardouille; Chris Bowen; Kara Matheson; Marvin J Fritzler Journal: Lupus Sci Med Date: 2022-06
Authors: Daniela Pinter; Thomas Gattringer; Christian Enzinger; Thomas Seifert-Held; Markus Kneihsl; Simon Fandler; Alexander Pichler; Christian Barro; Sebastian Eppinger; Lukas Pirpamer; Gerhard Bachmaier; Stefan Ropele; Joanna M Wardlaw; Jens Kuhle; Michael Khalil; Franz Fazekas Journal: J Cereb Blood Flow Metab Date: 2018-05-08 Impact factor: 6.200
Authors: Thomas Gattringer; Daniela Pinter; Christian Enzinger; Thomas Seifert-Held; Markus Kneihsl; Simon Fandler; Alexander Pichler; Christian Barro; Svenya Gröbke; Margarete Voortman; Lukas Pirpamer; Edith Hofer; Stefan Ropele; Reinhold Schmidt; Jens Kuhle; Franz Fazekas; Michael Khalil Journal: Neurology Date: 2017-10-18 Impact factor: 9.910
Authors: Tania F Gendron; Mohammed K Badi; Michael G Heckman; Karen R Jansen-West; George K Vilanilam; Patrick W Johnson; Alexander R Burch; Ronald L Walton; Owen A Ross; Thomas G Brott; Timothy M Miller; James D Berry; Katharine A Nicholson; Zbigniew K Wszolek; Björn E Oskarsson; Kevin N Sheth; Lauren H Sansing; Guido J Falcone; Brett L Cucchiara; James F Meschia; Leonard Petrucelli Journal: Sci Transl Med Date: 2020-11-11 Impact factor: 19.319
Authors: Marco Duering; Marek J Konieczny; Steffen Tiedt; Ebru Baykara; Anil Man Tuladhar; Esther van Leijsen; Philippe Lyrer; Stefan T Engelter; Benno Gesierich; Melanie Achmüller; Christian Barro; Ruth Adam; Michael Ewers; Martin Dichgans; Jens Kuhle; Frank-Erik de Leeuw; Nils Peters Journal: J Stroke Date: 2018-05-31 Impact factor: 6.967
Authors: Bianca Mages; Susanne Aleithe; Stephan Altmann; Alexandra Blietz; Björn Nitzsche; Henryk Barthel; Anja K E Horn; Constance Hobusch; Wolfgang Härtig; Martin Krueger; Dominik Michalski Journal: Front Cell Neurosci Date: 2018-06-18 Impact factor: 5.505